Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02608528|
Recruitment Status : Terminated (Poor Accrual)
First Posted : November 18, 2015
Last Update Posted : March 18, 2021
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer.
Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overall survival.
|Condition or disease||Intervention/treatment|
|Non-Small Cell Lung Cancer (NSCLC)||Radiation: [18F]fluoroglucose(FDG)|
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy|
|Actual Study Start Date :||October 22, 2015|
|Actual Primary Completion Date :||July 18, 2019|
|Actual Study Completion Date :||July 18, 2019|
- Number of inflammatory changes within the tumor [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608528
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Sharyn Katz, MD||Abramson Cancer Center of the University of Pennsylvania|